131 related articles for article (PubMed ID: 35887928)
1. A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains.
Zhang Z; He Q; Zhao W; Li Y; Yang J; Hu Z; Chen X; Peng H; Fu YX; Chen L; Lu L
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887928
[TBL] [Abstract][Full Text] [Related]
2. The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages.
He Q; Sun S; Chen X; Hu Z; Zhang Y; Peng H; Fu YX; Yang J; Chen L
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614948
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA; Yang YK; Zhang J; Xu K; Liang Y; Kang Y; Su JG; Yang T; Hussein S; ElDein MS; Shao S; Yang SS; Lei W; Gao XJ; Jiang Z; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Xiao P; Wang ZN; Yin JL; Mao XY; Zhang J; Liu N; Shen FJ; Qu L; Zhang YT; Yang XM; Wu G; Li QM
Signal Transduct Target Ther; 2022 Jun; 7(1):172. PubMed ID: 35665745
[TBL] [Abstract][Full Text] [Related]
4. The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.
Jiang H; Jin P; Guo X; Zhu J; Wang X; Wan P; Wan J; Liu J; Li J; Zhu F
Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140219
[TBL] [Abstract][Full Text] [Related]
5. Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
Hsieh SM; Chang SC; Cheng HY; Shih SR; Lien CE
Infect Dis Ther; 2022 Aug; 11(4):1493-1504. PubMed ID: 35579840
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.
Kaabi NA; Yang YK; Liang Y; Xu K; Zhang XF; Kang Y; Jin YQ; Hou JW; Zhang J; Yang T; Hussein S; ElDein MS; Lei ZH; Zhang H; Shao S; Liu ZM; Liu N; Zheng X; Su JG; Yang SS; Cong X; Tan Y; Lei W; Gao XJ; Jiang Z; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Xiao P; Shen FJ; Wu JJ; Han ZB; Du LF; Tang F; Chen S; Ma ZJ; Zheng F; Hou YN; Li XY; Li X; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM
Signal Transduct Target Ther; 2023 Jan; 8(1):20. PubMed ID: 36596779
[TBL] [Abstract][Full Text] [Related]
7. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
Front Immunol; 2022; 13():918896. PubMed ID: 35757764
[TBL] [Abstract][Full Text] [Related]
9. Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study.
Li J; Xie H; Chen W; Chen M; Bai S; Zhao W; Zhou T; Gao P; Zhang L; Wang Q; Pang X; Huang C; Wu J
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298542
[TBL] [Abstract][Full Text] [Related]
10. mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines.
Zhang B; Huo J; Huang Y; Teo SY; Duan K; Li Y; Toh LK; Lam KP; Xu S
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891221
[TBL] [Abstract][Full Text] [Related]
11. Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody.
Lai KT; Lai Wan Loong EY; Fung TL; Luk LW; Lau CC; Zee JS; Ma ES; Tang BS
Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455305
[TBL] [Abstract][Full Text] [Related]
12. Neutralization Activity against SARS-CoV-2 Variants after Booster Vaccination in Populations without COVID-19: A Meta-Analysis.
Cheng H; Peng Z; Si S; Alifu X; Zhou H; Chi P; Zhuang Y; Mo M; Yu Y
Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891263
[TBL] [Abstract][Full Text] [Related]
13. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
[TBL] [Abstract][Full Text] [Related]
15. Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant.
Khong KW; Liu D; Leung KY; Lu L; Lam HY; Chen L; Chan PC; Lam HM; Xie X; Zhang R; Fan Y; To KK; Chen H; Yuen KY; Chan KH; Hung IF
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214619
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization.
Xie H; Wen X; Li J; Chen W; Chen M; Zhang L; Lv M; Zhou S; Bai S; Zhao W; Wang J; Wu J
Int J Infect Dis; 2022 Apr; 117():97-102. PubMed ID: 35123028
[TBL] [Abstract][Full Text] [Related]
17. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1.
Davis-Gardner ME; Lai L; Wali B; Samaha H; Solis D; Lee M; Porter-Morrison A; Hentenaar IT; Yamamoto F; Godbole S; Douek DC; Lee FE; Rouphael N; Moreno A; Pinsky BA; Suthar MS
bioRxiv; 2022 Nov; ():. PubMed ID: 36380757
[TBL] [Abstract][Full Text] [Related]
18. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
